圣湘生物科技股份有限公司 二〇二五年七月 圣湘生物科技股份有限公司（688289）2025 年第三次临时股东大会会议资料 议案一：圣湘生物科技股份有限公司关于《公司 2025 年限制性股票激励计划（草 议案二：圣湘生物科技股份有限公司关于《公司 2025 年限制性股票激励计划实 议案三：圣湘生物科技股份有限公司关于提请股东大会授权董事会办理公司限制 议案四：圣湘生物科技股份有限公司关于不再设置监事会、修订《公司章程》并 议案五：圣湘生物科技股份有限公司关于董事会换届选举暨提名第三届董事会非 议案六：圣湘生物科技股份有限公司关于董事会换届选举暨提名第三届董事会独 圣湘生物科技股份有限公司（688289）2025 年第三次临时股东大会会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》以及 《圣湘生物科技股份有限公司章程》（以下简称"《公司章程》"）《圣湘生物科 技股份有限公司股东大会议事规则》等相关规定，圣湘生物科技股份有限公司（以 下简称"公 ...

圣湘生物科技股份有限公司 2025 年第三次临时股东大会会议资料 二〇二五年七月 圣湘生物科技股份有限公司（688289）2025 年第三次临时股东大会会议资料 目录 | 年第三次临时股东大会会议须知 2025 | 2 | | --- | --- | | 2025 年第三次临时股东大会会议议程 | 4 | | 议案一：圣湘生物科技股份有限公司关于《公司 年限制性股票激励计划（草 2025 | | | 案）》及其摘要的议案 | 6 | | 议案二：圣湘生物科技股份有限公司关于《公司 2025 年限制性股票激励计划实 | | | 施考核管理办法》的议案 | 7 | | 议案三：圣湘生物科技股份有限公司关于提请股东大会授权董事会办理公司限制 | | | 性股票激励计划相关事宜的议案 | 8 | | 议案四：圣湘生物科技股份有限公司关于不再设置监事会、修订《公司章程》并 | | | 办理工商变更登记及制定、修订部分治理制度的议案 | 10 | | 议案五：圣湘生物科技股份有限公司关于董事会换届选举暨提名第三届董事会非 | | | 独立董事候选人的议案 | 11 | | 议案六：圣湘生物科技股份有限公司关于董事会换届选 ...

Core Insights - The article highlights the rapid growth and strategic importance of the nano-metal materials industry in China, driven by technological advancements and increasing market demand [1][14]. Industry Overview - Nano-metal materials, characterized by grain sizes between 1-100 nanometers, exhibit superior properties such as ultra-high strength, excellent thermal stability, and unique electromagnetic characteristics [1][14]. - The market size for nano-metal materials in China is projected to grow from 28.98 billion yuan in 2018 to 74.451 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.03% [1][14]. - Key applications of nano-metal materials include electronics, new energy development, biomedicine, and aerospace [1][14]. Production Methods - The production methods for nano-metal materials are categorized into physical and chemical methods, including evaporation-condensation, high-energy ball milling, and chemical reduction [5]. Policy Support - The Chinese government has identified nano-materials as a key area for development, with various policies aimed at promoting innovation and industrial upgrades [7]. Industry Chain - The upstream of the nano-metal materials industry includes raw material supply and manufacturing equipment, while the downstream encompasses applications in biomedical, aerospace, construction, automotive, and electronics sectors [9]. Key Companies - Notable companies in the nano-metal materials sector include Jiangsu Boqian New Materials Co., Ltd., Jiangxi Baohong Nano Technology Co., Ltd., and Shandong Changxin Nano Technology Co., Ltd., which are involved in the R&D and production of high-performance nano-metal materials [17][19][21]. Development Trends - The industry is moving towards high-performance and multifunctional materials, with innovations in atomic-level structure design and surface modification technologies [25]. - There is a shift towards green and low-carbon production methods, emphasizing sustainable practices in the manufacturing of nano-metal materials [26][27]. - Cross-disciplinary integration is expanding the application boundaries of nano-metal materials, particularly in biomedicine and information technology [28].

证券代码：688289 证券简称：圣湘生物 公告编号：2025-046 圣湘生物科技股份有限公司 关于召开2025年第三次临时股东大会的 通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互 联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所科创板上市公司自律监管指引第 1 号 — 规范运作》 等有关规定执行。 二、 会议审议事项 本次股东大会审议议案及投票股东类型 投票股东类 序 型 重要内容提示： （二） 股东大会召集人：董事会 至2025 年 7 月 29 日 议案名称 号 A 股股东 非累积投票议案 关于《公司 2025 年限制性股票激励计划（草案）》及其摘要 的议案 ...

Core Viewpoint - The company has decided to abolish the supervisory board and amend its articles of association to enhance corporate governance and compliance with relevant laws and regulations [1][2]. Summary by Sections Abolishment of Supervisory Board - The company will no longer have a supervisory board, with its functions being transferred to the audit committee under the board of directors [1]. - This decision is in line with the provisions of the Company Law and aims to improve the company's governance structure [1][2]. Amendments to Articles of Association - The company plans to revise its articles of association to reflect the changes in governance structure and ensure compliance with the latest legal requirements [2]. - Key amendments include: - The definition of the company and its stakeholders has been broadened to include employees [2]. - The legal representative of the company will now be the director representing the company in executing its affairs [2]. - The total number of shares issued by the company remains at 579,388,006 [3]. - The company will not provide financial assistance for the acquisition of its shares, except for employee stock ownership plans [3]. Governance and Compliance - The company emphasizes the importance of adhering to the latest laws and regulations to enhance its governance level [2]. - The audit committee will now assume the supervisory functions previously held by the supervisory board, ensuring continued oversight of the company's operations [1][2].

关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688289 证券简称：圣湘生物 公告编号：2025-045 圣湘生物科技股份有限公司 根据相关规定，独立董事候选人的任职资格和独立性须经上海证券交易所审核无 异议后方可提交股东大会审议。公司将召开 2025 年第三次临时股东大会审议董事会 换届事宜，其中非独立董事、独立董事均采取累积投票制选举产生，自公司股东大会 审议通过之日起就任，任期三年。 公司第二届董事会独立董事曹亚女士、乔友林先生因在公司任期已届满六年，故 不再继续担任公司独立董事或其他职务。为保证公司董事会的正常运作，在公司 2025 年第三次临时股东大会审议通过上述换届事项前，公司第二届董事会仍按照《公司法》 和《公司章程》等相关规定继续履行董事职责。 二、其他情况说明 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）第二届董事会 任期即将届满，根据《中华人民共和国公司法》（以下简称"《公司法》"）《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司 ...

圣湘生物科技股份有限公司 章程 （2025 年第三次临时股东会审议通过） 二〇二五年七月 第一章总则 第一条 为维护圣湘生物科技股份有限公司（以下简称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》、《中华人民共和国市场主体登记管理条 例》和其他有关规定成立的股份有限公司。公司由湖南圣湘生物科技有限公司 整体变更发起设立，在长沙市市场监督管理局注册登记，取得营业执照, 统一 社会信用代码为 91430100673566826X。 第三条 公司于 2020 年 7 月 28 日经中国证券监督管理委员会 第六条 公司注册资本为人民币 579,388,006 元。 第七条 公司为永久存续的股份有限公司。 第八条 代表公司执行公司事务的董事为公司法定代表人。董事长为代表 公司执行事务的董事。担任法定代表人的董事或者经理辞任的，视为同时辞去 法定代表人。法定代表人辞任的，公司将在法定代表人辞任之日起三十日内确 定新的法定代表人。 法定代 ...

第二章 关联人和关联交易 第三条 公司关联人（关联方），指具有下列情形之一的自然人、法人或 其他组织： （一）直接或者间接控制公司的自然人、法人或其他组织； 圣湘生物科技股份有限公司 关联交易管理制度 第一章 总 则 第一条 为保证圣湘生物科技股份有限公司（以下简称：公司或本公司） 关联交易的公允性，保证公司各项业务通过必要的关联交易顺利地开展，规范公 司关联交易管理体系的建立，确保公司的关联交易行为不损害公司、公司债权人 和全体股东的利益，特别是中小投资者的合法权益，保证公司与关联人之间订立 的关联交易合同符合公平、公开、公允的原则，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上海证券交易所科创板股票上市规则》（以下简 称"《股票上市规则》"）等有关法律、法规，以及《公司章程》的规定，结合本 公司生产、经营的实际情况制定本制度。 第二条 公司发生关联交易，应当保证关联交易的合法性、必要性、合理 性和公允性，保持公司的独立性，不得利用关联交易输送利益或调节财务指标， 损害公司利益，不得以任何方式隐瞒关联关系。公司关联交易应当依照有关规定 严格履行决策程序和信息披露义务。 （三）公司董事、高级管 ...

General Principles - The rules are established to regulate company behavior and ensure shareholders can exercise their rights according to relevant laws and regulations [1][2] - The company must hold shareholder meetings in strict accordance with laws, regulations, and its articles of association [1][2] Types of Shareholder Meetings - Shareholder meetings are categorized into annual and extraordinary meetings, with annual meetings held within six months after the end of the previous fiscal year [1] - Extraordinary meetings must be convened within two months under specific circumstances, such as insufficient board members or significant losses [1] Convening Shareholder Meetings - The board of directors is responsible for convening meetings within the stipulated time frame [3][4] - Independent directors can propose extraordinary meetings, and the board must respond within ten days [3][4] - Shareholders holding more than 10% of shares can request extraordinary meetings, and the board must provide feedback within ten days [4][5] Proposals and Notifications - Proposals must fall within the scope of shareholder meeting authority and comply with legal requirements [6][7] - Shareholders holding at least 1% of shares can submit proposals ten days before the meeting [6][7] - Notifications for annual meetings must be sent 20 days in advance, while extraordinary meetings require 15 days' notice [7] Meeting Procedures - Meetings should be held at the company's registered address or a specified location, and can also utilize electronic communication methods [9][19] - Shareholders must present valid identification to attend meetings, and proxies must have written authorization [10][11] Voting and Decision-Making - Voting can be conducted through various methods, including electronic means, and results must be announced immediately [14][40] - The board must ensure that the meeting proceeds smoothly and address any disruptions [20][21] - Related shareholders must abstain from voting on matters where they have a conflict of interest [12][13] Record Keeping and Compliance - Meeting records must include details such as time, location, attendees, and voting results, and must be preserved for at least ten years [42][43] - Any resolutions passed must comply with legal standards, and disputes regarding the validity of resolutions can be taken to court [46][47] Implementation and Interpretation - The rules take effect upon approval by the shareholder meeting and are subject to interpretation by the board of directors [49][50]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Shengxiang Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, having complied with relevant laws and regulations [1][2][6]. Group 1: Company Background - Shengxiang Biotechnology was established by the transformation of Hunan Shengxiang Biotechnology Co., Ltd. and was officially registered on August 30, 2019 [4]. - The company received approval from the China Securities Regulatory Commission for its initial public offering, issuing 40 million shares on August 8, 2020, and is listed on the Shanghai Stock Exchange under the stock code 688289 [4]. Group 2: Legal Compliance - The law firm has verified that the company meets all legal requirements to proceed with the incentive plan, including the absence of any conditions that would necessitate termination or suspension of the plan [6][10]. - The firm has confirmed that the company has provided all necessary documentation and that there are no significant omissions or misrepresentations [2][3]. Group 3: Incentive Plan Details - The 2025 restricted stock incentive plan was approved by the company's board on July 10, 2025, and includes provisions for the purpose, management, and distribution of rights among the incentive recipients [7][10]. - The plan specifies that the funding for the incentive will come from the participants' own resources, with the company not providing any financial assistance [12]. Group 4: Impact on Stakeholders - The board's remuneration and assessment committee has indicated that the incentive plan is beneficial for the company's sustainable development and does not harm the interests of the company or its shareholders [12][13]. - The incentive plan's implementation is contingent upon further legal procedures and approval from the shareholders' meeting [9][14].